Quantitative review of antibody response to inactivated seasonal influenza vaccines

Please cite this paper as: Seidman et al. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6(1), 52–62.

[1]  M. Muszkat,et al.  Response to influenza vaccination in community and in nursing home residing elderly: relation to clinical factors , 2003, Experimental Gerontology.

[2]  G. K. Hirst.  THE AGGLUTINATION OF RED CELLS BY ALLANTOIC FLUID OF CHICK EMBRYOS INFECTED WITH INFLUENZA VIRUS. , 1941, Science.

[3]  R. Betts,et al.  Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. , 1996, The Journal of infectious diseases.

[4]  E. Walter,et al.  Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? , 2010, Vaccine.

[5]  K. Cantell,et al.  Immune response to inactivated influenza virus vaccine: antibody reactivity with epidemic influenza B viruses of two highly distinct evolutionary lineages. , 1992, Vaccine.

[6]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.

[7]  J. Wood,et al.  Comparison of influenza serological techniques by international collaborative study. , 1994, Vaccine.

[8]  S. Gravenstein,et al.  Efficacy of an Influenza Hemagglutinin‐Diphtheria Toxoid Conjugate Vaccine in Elderly Nursing Home Subjects During an Influenza Outbreak , 1994, Journal of the American Geriatrics Society.

[9]  F. Newman,et al.  Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. , 2001, Vaccine.

[10]  P. Gross,et al.  Immune response to influenza vaccination in a large healthy elderly population. , 1999, Vaccine.

[11]  C. V. Hoecke,et al.  Immunogenicity and safety of influenza vaccination in 3- to 6-year-old children with a two dose immunisation schedule , 1996, European Journal of Pediatrics.

[12]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[13]  A. Floreani,et al.  Comparison of three different influenza vaccines in institutionalised elderly. , 2001, Vaccine.

[14]  N. Cox,et al.  Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. , 1996, The Journal of infectious diseases.

[15]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2012, The Cochrane database of systematic reviews.

[16]  E. H. Lennette,et al.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic. , 1952, American journal of hygiene.

[17]  W. Keitel,et al.  Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States , 2005, Human vaccines.

[18]  R. Couch,et al.  Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. , 2006, The Journal of infectious diseases.

[19]  V Demicheli,et al.  Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review , 2005, The Lancet.

[20]  A. Podda,et al.  MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis , 2008, Influenza and other respiratory viruses.

[21]  R. Prymula,et al.  Evaluation of reactogenicity and immunogenicity of two influenza vaccines (vaxigrip and fluarix) in the season 1996-1997. , 1998, Central European journal of public health.

[22]  B. Lina,et al.  A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. , 2000, Biologicals : journal of the International Association of Biological Standardization.

[23]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[24]  R. Couch,et al.  Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly , 1996, Clinical and diagnostic laboratory immunology.

[25]  B. L. Beattie,et al.  Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. , 1993, Vaccine.

[26]  G. Zuccotti,et al.  The virosomal adjuvanted influenza vaccine , 2010, Expert opinion on biological therapy.

[27]  P. Villari,et al.  Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. , 2004, Vaccine.

[28]  A. Iorio,et al.  Possible correlation between low antigenic drift of A(H1N1) influenza viruses and induction of HI antibodies , 1996, European Journal of Epidemiology.

[29]  W. O'Fallon,et al.  Value of Immunological Markers in Predicting Responsiveness to Influenza Vaccination in Elderly Individuals , 2001, Journal of Virology.

[30]  Y. Barenholz,et al.  Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. , 2003, Vaccine.

[31]  R. Belshe,et al.  Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. , 1995, The Journal of infectious diseases.

[32]  A. Grosche,et al.  Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people. , 1993, Vaccine.

[33]  D. Jahnigen,et al.  Antibody Response of an Elderly Population to a Supplemental Dose of Influenza B Vaccine , 1988, Journal of the American Geriatrics Society.

[34]  J. Wood,et al.  The use of correlates of immunity in European Union licensing of influenza vaccines. , 2003, Developments in biologicals.

[35]  Libo Dong,et al.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. , 2009, The New England journal of medicine.

[36]  G. Glenn,et al.  Dose sparing with intradermal injection of influenza vaccine. , 2004, The New England journal of medicine.

[37]  G. Gaedicke,et al.  Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children , 2004, The Pediatric infectious disease journal.

[38]  Keiji Fukuda,et al.  Influenza-associated hospitalizations in the United States. , 2004, JAMA.

[39]  C. Schwenke,et al.  Preservative-free influenza vaccine. , 2000, Immunology letters.

[40]  C. Herzog,et al.  Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. , 2009, Vaccine.

[41]  L. Brydak,et al.  Antibody response to influenza vaccination in healthy adults. , 2004, Viral immunology.

[42]  E. Gardner,et al.  Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly , 2002, Experimental Gerontology.

[43]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[44]  A. Palache,et al.  Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. , 1997, The Journal of infectious diseases.

[45]  S. Halperin,et al.  Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. , 1998, Vaccine.

[46]  R. Douglas,et al.  Immunization of elderly people with two doses of influenza vaccine , 1987, Journal of clinical microbiology.

[47]  A S Perelson,et al.  Variable efficacy of repeated annual influenza vaccination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[49]  Antonio Boccia,et al.  The Efficacy of Influenza Vaccine for Healthy Children: A Meta-Analysis Evaluating Potential Sources of Variation in Efficacy Estimates Including Study Quality , 2007, The Pediatric infectious disease journal.

[50]  R. Couch,et al.  Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge , 1982, Infection and immunity.

[51]  B. Ruf,et al.  Open, Randomized Study to Compare the Immunogenicity and Reactogenicity of an Influenza Split Vaccine with an MF59-Adjuvanted Subunit Vaccine and a Virosome-Based Subunit Vaccine in Elderly , 2004, Infection.

[52]  C W Potter,et al.  Determinants of immunity to influenza infection in man. , 1979, British medical bulletin.

[53]  R. Holman,et al.  Decreased antibody response among nursing home residents who received recalled influenza vaccine and results of revaccination, 1996-97. , 2000, Vaccine.

[54]  J. Treanor,et al.  Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. , 2006, Vaccine.

[55]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[56]  Bill Wilson,et al.  In a relationship , 2013 .

[57]  S. Cryz,et al.  Immunogenicity of new virosome influenza vaccine in elderly people , 1994, The Lancet.

[58]  A. Osterhaus,et al.  On the relationship between mean antibody level, seroprotection and clinical protection from influenza. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[59]  R. Betts,et al.  Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults , 1990, Journal of clinical microbiology.

[60]  Y. Barenholz,et al.  Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults , 2003, Journal of medical virology.

[61]  D. Powers.  Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women , 1994, Clinical and diagnostic laboratory immunology.

[62]  B. Murphy,et al.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory , 1991, Journal of clinical microbiology.

[63]  R. Schmidt-Ott,et al.  Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. , 2007, Vaccine.

[64]  A. Podda,et al.  MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development? , 2007, Clinical pharmacology and therapeutics.

[65]  A. Osterhaus,et al.  Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. , 1999, Archives of internal medicine.

[66]  F. Pregliasco,et al.  Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly , 2001, Aging.

[67]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[68]  A. Osterhaus,et al.  Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. , 1996, Vaccine.

[69]  R. Glück,et al.  Virosomes as carriers for combined vaccines. , 1995, Vaccine.

[70]  R. Betts,et al.  Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. , 1996, The Journal of infectious diseases.

[71]  R. Rappuoli,et al.  An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. , 2006, Vaccine.

[72]  R. Belshe,et al.  Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. , 1993, The Journal of infectious diseases.

[73]  T. Mabrouk,et al.  A Phase I, randomized controlled clinical trial to study the reactogenicity and immunogenicity of a new split influenza vaccine derived from a non-tumorigenic cell line. , 1999, Developments in biological standardization.

[74]  K. Cantell,et al.  Vaccination-induced HI antibody to influenza A(H1N1) viruses in poorly primed adults under circumstances of low antigenic drift. , 1993, Vaccine.

[75]  B. Murphy,et al.  Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. , 1988, The Journal of infectious diseases.

[76]  A. Floreani,et al.  Response to influenza vaccine in people with non-protective HI antibody titers , 2006, European Journal of Epidemiology.

[77]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[78]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[79]  R. Betts,et al.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. , 1999, Vaccine.

[80]  J. Wood,et al.  The influenza vaccine licensing process. , 2003, Vaccine.

[81]  C. Bridges,et al.  Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. , 2006, The Journal of infectious diseases.

[82]  M. Basileo,et al.  Effects of Repeated Annual Influenza Vaccination on Antibody Responses against Unchanged Vaccine Antigens in Elderly Frail Institutionalized Volunteers , 2007, Gerontology.

[83]  R. Bugarini,et al.  Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers , 2006, Journal of Virology.

[84]  P. Duff,et al.  Influenza vaccine. , 2013, Paediatrics & child health.

[85]  E. Lupulescu,et al.  Comparative study of the immunogenicity of aqueous versus aluminium phosphate adsorbed split influenza vaccine C.I. , 1989, Archives roumaines de pathologie experimentales et de microbiologie.

[86]  J. Myśliwska,et al.  Immune Response to Influenza Vaccination in an Elderly Population , 2003, Journal of Clinical Immunology.

[87]  R. Couch,et al.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults , 1994, Journal of clinical microbiology.

[88]  V. Prikazsky,et al.  Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. , 1996, Gerontology.

[89]  M. Zambon,et al.  Confronting the avian influenza threat: vaccine development for a potential pandemic , 2004, The Lancet Infectious Diseases.

[90]  Cecile Viboud,et al.  Impact of influenza vaccination on seasonal mortality in the US elderly population. , 2005, Archives of internal medicine.

[91]  I. Donatelli,et al.  Antibody Response to 1995–1996 Influenza Vaccine in Institutionalized and Non-Institutionalized Elderly Women , 1998, Gerontology.

[92]  F. Newman,et al.  Serum antibody responses after intradermal vaccination against influenza. , 2004, The New England journal of medicine.

[93]  L. Biasio,et al.  Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. , 2003, Vaccine.

[94]  Henry F. Diaz,et al.  ENSO variability, teleconnections and climate changeThis article is a US Government work and is in the public domain in the USA. , 2001 .

[95]  G. Jonson,et al.  The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[96]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[97]  S. Cryz,et al.  Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. , 1997, Vaccine.

[98]  Mark Wolff,et al.  Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. , 2002, Vaccine.

[99]  G. Lüchters,et al.  Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? , 2004, Virus research.

[100]  R. Gasparini,et al.  Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects , 2004, European Journal of Epidemiology.